{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:46:34Z","timestamp":1790221594437,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74241-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:28:11Z","timestamp":1781278091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangzhou","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuofang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangqin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Dong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-9487","authenticated-orcid":false,"given":"Chunxia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"74241_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"74241_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","volume":"134","author":"M Dietel","year":"2019","unstructured":"Dietel, M. et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer 134, 174\u2013179 (2019).","journal-title":"Lung Cancer"},{"key":"74241_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11074-z","volume":"23","author":"H Bailey","year":"2023","unstructured":"Bailey, H. et al. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer 23, 603 (2023).","journal-title":"BMC Cancer"},{"key":"74241_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 41, 1999\u20132006 (2023).","journal-title":"J. Clin. Oncol."},{"key":"74241_CR5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"74241_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jtho.2024.05.376","volume":"19","author":"F Perrone","year":"2024","unstructured":"Perrone, F., Leonetti, A., Tiseo, M. & Facchinetti, F. Benefit with no target: long-term outcomes of chemoimmunotherapy in \u201cPD-L1 negative\u201d NSCLC. J. Thorac. Oncol. 19, 1128\u20131132 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR7","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jtho.2024.04.011","volume":"19","author":"SM Gadgeel","year":"2024","unstructured":"Gadgeel, S. M. et al. Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score less than 1%: pooled analysis of outcomes after five years of follow-up. J. Thorac. Oncol. 19, 1228\u20131241 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.  N. Engl. J. Med. 381, 1535\u20131546 (2019).","journal-title":"N. Engl. J. Med."},{"key":"74241_CR9","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau, T. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the Checkmate 040 randomized clinical trial. JAMA Oncol. 6, e204564 (2020).","journal-title":"JAMA Oncol."},{"key":"74241_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer.  N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"74241_CR11","first-page":"289","volume":"17","author":"LG Paz-Ares","year":"2022","unstructured":"Paz-Ares, L. G. et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 17, 289\u2013308 (2022).","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"74241_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares, L. et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 198\u2013211 (2021).","journal-title":"Lancet Oncol."},{"key":"74241_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jtho.2024.11.005","volume":"20","author":"J Tanizaki","year":"2025","unstructured":"Tanizaki, J. Finding the right match: who should opt for anti-CTLA-4 and programmed cell death protein-1 combination therapy? J. Thorac. Oncol. 20, 27\u201329 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jtho.2024.09.1439","volume":"20","author":"S Peters","year":"2025","unstructured":"Peters, S. et al. Long-term survival outcomes with first-line nivolumab plus ipilimumab-based treatment in patients with metastatic NSCLC and tumor programmed death-ligand 1 lower than 1%: a pooled analysis. J. Thorac. Oncol. 20, 94\u2013108 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","volume":"16","author":"L Liu","year":"2021","unstructured":"Liu, L. et al. Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J. Thorac. Oncol. 16, 1099\u20131117 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(24)00185-1","volume":"12","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi, Y. et al. Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir. Med 12, 877\u2013887 (2024).","journal-title":"Lancet Respir. Med"},{"key":"74241_CR17","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1158\/1538-7445.AM2018-3827","volume":"78","author":"B Li","year":"2018","unstructured":"Li, B., Huang, Z., Pang, X., Zhong, T. & Xia, M. Y. Abstract 3827: Bispecific antibodies with an anti-PD-1 backbone for cancer therapy generate enhanced immune activity. Cancer Res. 78, 3827\u20133827 (2018).","journal-title":"Cancer Res."},{"key":"74241_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41591-024-03450-4","volume":"31","author":"L Shen","year":"2025","unstructured":"Shen, L. et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat. Med. 31, 1163\u20131170 (2025).","journal-title":"Nat. Med."},{"key":"74241_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","volume":"130","author":"B Chen","year":"2024","unstructured":"Chen, B. et al. A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer. Br. J. Cancer 130, 450\u2013456 (2024).","journal-title":"Br. J. Cancer"},{"key":"74241_CR20","doi-asserted-by":"publisher","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","volume":"33","author":"MJ Ahn","year":"2022","unstructured":"Ahn, M. J. et al. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) non-small cell lung cancer (NSCLC): a phase Ib\/II trial. Ann. Oncol. 33, S1423 (2022).","journal-title":"Ann. Oncol."},{"key":"74241_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jtho.2022.08.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares, L. G. et al. Safety of first-line nivolumab plus ipilimumab in patients with metastatic NSCLC: a pooled analysis of CheckMate 227, CheckMate 568, and CheckMate 817. J. Thorac. Oncol. 18, 79\u201392 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51271-3","volume":"15","author":"H Singh","year":"2024","unstructured":"Singh, H. et al. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma. Nat. Commun. 15, 6833 (2024).","journal-title":"Nat. Commun."},{"key":"74241_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jtho.2024.09.1385","volume":"20","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. High-dose furmonertinib in patients with EGFR-mutated NSCLC and leptomeningeal metastases: a prospective real-world study. J. Thorac. Oncol. 20, 65\u201375 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"74241_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun. 9, 5068 (2018).","journal-title":"Nat. Commun."},{"key":"74241_CR25","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.1703577114","volume":"114","author":"X Hao","year":"2017","unstructured":"Hao, X. et al. DNA methylation markers for diagnosis and prognosis of common cancers. Proc. Natl. Acad. Sci. USA. 114, 7414\u20137419 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74241_CR26","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","volume":"3","author":"F Chemi","year":"2022","unstructured":"Chemi, F. et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat. Cancer 3, 1260\u20131270 (2022).","journal-title":"Nat. Cancer"},{"key":"74241_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-022-01387-4","volume":"14","author":"F Janke","year":"2022","unstructured":"Janke, F. et al. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. Clin. Epigenetics 14, 163 (2022).","journal-title":"Clin. Epigenetics"},{"key":"74241_CR28","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer, N. et al. A DNA methylation atlas of normal human cell types. Nature 613, 355\u2013364 (2023).","journal-title":"Nature"},{"key":"74241_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda, M. A. et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann. Oncol. 35, 267\u2013275 (2024).","journal-title":"Ann. Oncol."},{"key":"74241_CR30","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel, S. et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer. J. Clin. Oncol. 38, 1505\u20131517 (2020).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74241-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74241-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:13:19Z","timestamp":1785517999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74241-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74241"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74241-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Haoran Tang, Hang Dong, and Shidong Jia disclosed that they were employees of Huidu Shanghai Medicine Ltd. Yichao Zang is an employee of Akeso Biopharma. No disclosures were reported by the other authors. The other authors declared no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7483"}}